Lista de obras - Isabella Caligiuri - Dominio Público Uruguay

4-Aryliden-2-methyloxazol-5(4H)-one as a new scaffold for selective reversible MAGL inhibitors

artículo científico publicado en 2015

A Guide to PIN1 Function and Mutations Across Cancers

artículo científico publicado en 2018

A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).

artículo científico publicado en 2017

Androgen receptor serine 81 mediates Pin1 interaction and activity

artículo científico publicado en 2012

Binding investigation and preliminary optimisation of the 3-amino-1,2,4-triazin-5(2H)-one core for the development of new Fyn inhibitors.

artículo científico publicado en 2018

Bottom-up synthesis of carbon nanoparticles with higher doxorubicin efficacy.

artículo científico publicado en 2017

CDK inhibitors: from the bench to clinical trials.

artículo científico publicado en 2010

Characterization of the Saffron Derivative Crocetin as an Inhibitor of Human Lactate Dehydrogenase 5 in the Antiglycolytic Approach against Cancer.

artículo científico publicado en 2017

Computationally driven discovery of phenyl(piperazin-1-yl)methanone derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors

artículo científico publicado en 2019

Critical choices for modeling breast cancer in transgenic mouse models.

artículo científico publicado en 2012

Development of terphenyl-2-methyloxazol-5(4H)-one derivatives as selective reversible MAGL inhibitors.

artículo científico publicado en 2017

Discovery of long-chain salicylketoxime derivatives as monoacylglycerol lipase (MAGL) inhibitors

scientific article published on 16 August 2018

Dissecting Pin1 and phospho-pRb regulation.

artículo científico publicado en 2013

Enhanced Chemotherapeutic Behavior of Open-Caged DNA@Doxorubicin Nanostructures for Cancer Cells

artículo científico publicado en 2015

Exosomal doxorubicin reduces the cardiac toxicity of doxorubicin

artículo científico publicado en 2015

Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models.

artículo científico publicado en 2016

First-of-its-kind STARD3 Inhibitor: In Silico Identification and Biological Evaluation as Anticancer Agent

scientific article published on 20 February 2019

Highly selective salicylketoxime-based estrogen receptor β agonists display antiproliferative activities in a glioma model

artículo científico publicado en 2015

Identification and characterization of a new reversible MAGL inhibitor

artículo científico publicado en 2014

Identification of new Fyn kinase inhibitors using a FLAP-based approach.

artículo científico publicado en 2013

Liposomal delivery of a Pin1 inhibitor complexed with cyclodextrins as new therapy for high-grade serous ovarian cancer

scientific article published on 08 May 2018

New insight into structure-activity of furan-based salicylate synthase (MbtI) inhibitors as potential antitubercular agents

scientific article published on 01 December 2019

Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor

artículo científico publicado en 2019

Pin1 and nuclear receptors: a new language?

artículo científico publicado en 2013

Proof-of-Concept Multistage Biomimetic Liposomal DNA Origami Nanosystem for the Remote Loading of Doxorubicin

scientific article published on 31 January 2019

Rational Development of MAGL Inhibitors

artículo científico publicado en 2018

Retinoblastoma tumor-suppressor protein phosphorylation and inactivation depend on direct interaction with Pin1.

artículo científico publicado en 2012

Self-Therapeutic Cobalt Hydroxide Nanosheets (Co(OH)<sub>2</sub> NS) for Ovarian Cancer Therapy

artículo científico publicado en 2021

Synthesis and in-depth studies on the anticancer activity of novel palladacyclopentadienyl complexes stabilized by N-Heterocyclic carbene ligands

scientific article published on 22 June 2019

The Clinical translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes.

artículo científico publicado en 2017

The prolyl isomerase Pin1 acts synergistically with CDK2 to regulate the basal activity of estrogen receptor α in breast cancer

artículo científico publicado en 2013

Treatment for glioma recurrence: new hope?

artículo científico publicado en 2010

Virtual screening identifies a PIN1 inhibitor with possible antiovarian cancer effects

scientific article published on 29 January 2019

pRb controls estrogen receptor alpha protein stability and activity.

artículo científico publicado en 2013

Lista de obras de Isabella Caligiuri

4-Aryliden-2-methyloxazol-5(4H)-one as a new scaffold for selective reversible MAGL inhibitors

A Guide to PIN1 Function and Mutations Across Cancers

A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).

Androgen receptor serine 81 mediates Pin1 interaction and activity

Binding investigation and preliminary optimisation of the 3-amino-1,2,4-triazin-5(2H)-one core for the development of new Fyn inhibitors.

Bottom-up synthesis of carbon nanoparticles with higher doxorubicin efficacy.

CDK inhibitors: from the bench to clinical trials.

Characterization of the Saffron Derivative Crocetin as an Inhibitor of Human Lactate Dehydrogenase 5 in the Antiglycolytic Approach against Cancer.

Computationally driven discovery of phenyl(piperazin-1-yl)methanone derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors

Critical choices for modeling breast cancer in transgenic mouse models.

Development of terphenyl-2-methyloxazol-5(4H)-one derivatives as selective reversible MAGL inhibitors.

Discovery of long-chain salicylketoxime derivatives as monoacylglycerol lipase (MAGL) inhibitors

Dissecting Pin1 and phospho-pRb regulation.

Enhanced Chemotherapeutic Behavior of Open-Caged DNA@Doxorubicin Nanostructures for Cancer Cells

Exosomal doxorubicin reduces the cardiac toxicity of doxorubicin

Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models.

First-of-its-kind STARD3 Inhibitor: In Silico Identification and Biological Evaluation as Anticancer Agent

Highly selective salicylketoxime-based estrogen receptor β agonists display antiproliferative activities in a glioma model

Identification and characterization of a new reversible MAGL inhibitor

Identification of new Fyn kinase inhibitors using a FLAP-based approach.

Liposomal delivery of a Pin1 inhibitor complexed with cyclodextrins as new therapy for high-grade serous ovarian cancer

New insight into structure-activity of furan-based salicylate synthase (MbtI) inhibitors as potential antitubercular agents

Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor

Pin1 and nuclear receptors: a new language?

Proof-of-Concept Multistage Biomimetic Liposomal DNA Origami Nanosystem for the Remote Loading of Doxorubicin

Rational Development of MAGL Inhibitors

Retinoblastoma tumor-suppressor protein phosphorylation and inactivation depend on direct interaction with Pin1.

Self-Therapeutic Cobalt Hydroxide Nanosheets (Co(OH)<sub>2</sub> NS) for Ovarian Cancer Therapy

Synthesis and in-depth studies on the anticancer activity of novel palladacyclopentadienyl complexes stabilized by N-Heterocyclic carbene ligands

The Clinical translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes.

The prolyl isomerase Pin1 acts synergistically with CDK2 to regulate the basal activity of estrogen receptor α in breast cancer

Treatment for glioma recurrence: new hope?

Virtual screening identifies a PIN1 inhibitor with possible antiovarian cancer effects

pRb controls estrogen receptor alpha protein stability and activity.